IL17F免疫遗传标记预测直肠癌新辅助放化疗后转移与总生存
该研究在370例接受术前放化疗及手术的局部晚期直肠癌(LARC)患者中分析了34个免疫应答相关基因的192个多态性,分测试集(n=233)与验证集(n=137)。两个IL17F标记(rs641701、rs9463772)在兩集均与2年无复发生存显著相关,并与5年无转移生存、5年无病生存及10年总生存相关;TRG与基因型联合可区分预后亚组。
要点
- IL17F-rs641701与rs9463772在测试集和验证集中均显著预测2年无复发生存(bootstrapped P<0.05)。
- 两标记与5年无病生存、5年无转移生存及10年总生存显著相关。
- TRG联合IL17F基因型可识别5年DFS与10年OS显著不同的预后亚组。
核心结论
- IL17F-rs641701和IL17F-rs9463772是与LARC患者预后显著相关的有前景的免疫遗传标记。
- 经前瞻性验证后,TRG联合患者基因型可考虑作为个体化多模式治疗选择的额外分层标准。
研究设计与样本
- 在370例接受术前放化疗及手术的LARC患者中分析34个免疫应答信号网络候选基因的192个多态性。
- 患者分为测试集(n=233)和验证集(n=137)。
- 标记选择基于在测试集和验证集中对2年无复发生存(2-yrRFS)均有一致显著效应(bootstrapped P<0.05)。
- 所选免疫遗传变异对5年无转移生存(5yrMFS)、5年无病生存(5yrDFS)和10年总生存(10yrOS)的效应在全部370例患者中检验。
主要发现
- 两个IL17F标记(IL17F-rs641701和IL17F-rs9463772)可预测2yrRFS、5yrDFS、5yrMFS和10yrOS。
- TRG联合IL17F-rs641701基因型识别出5yrDFS(HR 11.29,P<0.001)和10yrOS(HR 7.07,P=0.005)差异显著的亚组。
- TRG联合IL17F-rs9463772基因型识别出5yrDFS(HR 5.86,P=0.001)和10yrOS(HR 6.05,P=0.002)差异显著的亚组。
关键数值与推荐
- 标记选择标准:在测试集和验证集中对2-yrRFS均有一致显著效应(bootstrapped P<0.05)。
- TRG联合IL17F-rs641701:5yrDFS HR 11.29(P<0.001),10yrOS HR 7.07(P=0.005)。
- TRG联合IL17F-rs9463772:5yrDFS HR 5.86(P=0.001),10yrOS HR 6.05(P=0.002)。
临床怎么用
- IL17F-rs641701和IL17F-rs9463772有望作为LARC患者预后评估的免疫遗传标记。
- TRG联合IL17F基因型可辅助识别预后不同的LARC亚组,为个体化多模式治疗提供分层依据。
- 上述发现需前瞻性验证后方可用于临床决策。
局限性
- 研究结论明确需前瞻性验证后方可考虑将TRG联合基因型用于治疗分层。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The role of the immune system in tumor response to chemo-radiotherapy (CRT) is an emerging issue. This work aimed at identifying predictive and prognostic immunogenetic variants in LARC patients after preoperative (po)-CRT and surgery. MATERIALS AND METHODS: A set of 192 polymorphisms in 34 candidate genes involved in the regulation of the immune response signalling network, was selected and analyzed in 370 LARC patients treated with po-CRT and surgery, split into a Test Set (n = 233) and a Validation Set (n = 137). Immunogenetic markers were selected based on a concordant significant effect on 2-year relapse-free survival (2-yrRFS) (bootstrapped P < 0.05) in both patients Sets. The effect of the selected immunogenetic variants on 5-year metastases-free (5yrMFS), 5-year disease-free (5yrDFS), and 10-year overall (10yrOS) survival was tested in the entire Set of 370 patients. RESULTS: Two immunogenetic IL17F (IL17F-rs641701 and IL17F-rs9463772) markers predictive of 2yrRFS, 5yrDFS, 5yrMFS, and 10yrOS were identified. The combination of tumor regression grade (TRG) and patients genotype for IL17F-rs641701 and IL17F-rs9463772 allowed the identification of subgroups of patients with differential prognosis in term of both 5yrDFS (HR 11.29, P-value <0.001, and HR 5.86, P-value = 0.001, respectively) and 10yrOS (HR 7.07, P-value = 0.005, and HR 6.05, P-value = 0.002, respectively). CONCLUSION: IL17F-rs641701 and IL17F-rs9463772 were highlighted as promising immunogenetic markers significantly associated with the prognosis of LARC patients. After a prospective validation of the herein reported findings, the combination of TRG and patients genotype should be considered to provide additional stratification criteria for the selection of a personalized multimodality treatment.
引用
- Cecchin E, De Mattia E, Dreussi E, et al. Immunogenetic markers in IL17F predict the risk of metastases spread and overall survival in rectal cancer patients treated with neoadjuvant chemoradiotherapy. Radiother Oncol. 2020. PMID: 32387487. doi:10.1016/j.radonc.2020.04.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。